Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer!

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...

ADT speeds coronary atherosclerosis, with greater effects with use of the GnRH-agonist leuprolide compared with the GnRH-antagonist relugolix. Coronary atherosclerosis may progress more over 12 months ...

Leuprolide acetate 45mg; per kit; depot susp for IM inj; preservative-free. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). <1yr: not established. ≥1yrs: ...

LUPRON DEPOT-3 MONTH 11.25mg prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the ...